Pharma giant AbbVie has kicked off 2023 by disclosing two strategic collaborations in quick succession. The company entered into a multi-year collaboration with Immunome, paying US$30 M upfront to discover multiple novel oncology targets leveraging the latter’s Discovery Engine technology. Shortly afterwards, AbbVie disclosed its partnership with Anima Biotech to discover and develop mRNA biology modulators against oncology and immunology targets. AbbVie will pay Anima an upfront payment of US$42 M to gain access to its mRNA Lightning technology platform.